

The Palliative Curative Treatment of Untreatable Metastatic Solid Tumor Patients by a Psycho-Neuroendocrino-Immunophytotherapeutic (PNEIF) Regimen with Natural Anticancer Agents

Paolo Lissoni¹, Giusy Messina^{1*}, Fernando Brivio¹, Franco Rovelli¹, Luca Fumagalli² and Giuseppe Di Fede³

¹International Institute of Psychoneuroendocrinoimmunology, Milan, Italy

²Manzoni Hospital, Surgery Department, Lecco, Italy

³Institute of Biological Medicine, Milan, Italy

*Corresponding author: Giusy Messina, International Institute of Psychoneuroendocrinoimmunology, Milan, Italy; Tel: +39026693950; Fax: +39026700708; E-mail: giusy.messina@iipn.it

Received date: Feb 23, 2017; Accepted date: Mar 21, 2017; Published date: Mar 25, 2017

Copyright: © 2016 Paolo, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Several natural agents, including both human endogenous neuroendocrine substances, namely the pineal hormones, and plants, mainly *Aloe*, *Myrrh* and *Magnolia*, have been proven to exert anticancer activities, due to antiproliferative and immunomodulating properties. On this basis, a study was planned in an attempt to evaluate the therapeutic efficacy of a psychoneuroendocrinoimmun-phytotherapeutic (PNEIF) regimen with pineal hormones and antitumor plants in a group of untreatable metastatic solid tumor patients, for whom no treatment other than the palliative therapy was available, because of lack of response to previous chemotherapies, poor clinical status or personal refusal of chemotherapy, and with a life expectancy less than 1 year. The pineal hormone melatonin (MLT) and 5-methoxytryptamine (5-MTT) were given orally at 100 mg/day in the dark period and at 5 mg in the light period of the day, respectively, in association with *Aloe* and *Myrrh* mixture at 10 ml thrice/day, *Magnolia* cortex at 500 mg twice/day and *Bowellia* at 1000 mg/day in patients with brain metastases. A complete response (CR) and partial response (PR) were achieved in 2 and in 8 patients. Then, an objective tumor regression was obtained in 10/132 (8%) patients. A stable disease (SD) was found in 61 patients, then a disease control (DC), consisting of CR plus PR plus SD, was achieved in 71/132 (54%) patients, whereas the remaining patients had a progressive disease (PD). A survival longer than 1 year was seen in 63/132 (48%) patients, and the percent of 2 and 3-year survival obtained in patients with response or SD was significantly longer than that found in patients with PD. The treatment was well tolerated and no relevant biological toxicity occurred. This preliminary study would demonstrate that a PNEIF combination with natural anticancer agents may prolong the survival time in patients, for whom no standard therapy was available other than the only palliative therapy, and with an expected survival less than 1 year.

Keywords: 5b|jWbWf` d`Ubg` BUhfU` UbjWbWf` U`Ybg` D|bYU
`cfa cbYg

Introduction

HXLñh fY|gbc`Xci VhUci hñYZ bXLà YbU`ja dcfHbWcZhY
ja a i bYgñhà `|b`hYwblfc`cZwBwF`[fckh`UbXh`Uih`YubjWbWf`
ja a i b|lm|g`bLà YmiU`na d`cWm`Xdy`Xbh`d`Ybca`Ycb`Q%Q`Ug
Xá cbgfUH`XVrh`YZWm`h`Uih`Yy`|XbWcZ`na d`cWm`dY|U|g`cbY
cZhYa`cgnbY`Uj`Ydfc`|bcg|WZwMf`|b`WbWf`dUjYbg`Q`Q`K`|h`
fygdWwlc`hY`dngc`c`mcZhY`Ub|li`a`cf`|a`a`i`bY`fyg|cbgZ`hY`
UbjWbWf`dchbWcZhY`ja a i bYgñhà`W`i`XVYZ`fh`Y`Yb`UbWX`
UbX`amplifed`U`Ygh`Zca`U`h`Ycfh`W`dc|bhcZj`|K`h`fci`[\`|kc`
different`gfUM`|Yg`Wbg|b`|fc|Y`Z`T`Q`

dfYgbh]hifYdfYgbhghYcbma c'YWYYI]gh]b| ']b'hYkcf'XWdUVYcZ
Wi bhfUW]b| 'hY c]YFU' a U]b' d\Ug' fYgcbgVY Zf' WbWf
dfc[fYg]cbz]bWX]b| 'hY `cgg' cZ hY Ucdclh]WdfcWgg UbX hY
dYfgd]bhUW] U]cb'cZW' g fZWfYWd]c'fgZf' h a cf' [fck h' ZWf'g'
g W'Ug'Yd]Xfa U' [fck h' ZWf' fB; : EzhYUhfU]cb'cZ]bhfW'i 'U'
'1 bW]cbg UbX hY Wbg'ei YbhWU]Y]b'hY]bhfW'i 'U' a Uf]l' UbX
hY g]a i 'U]cb'cZ hY U]b|]c| YbYg'g' UbX WbWf'fYU]X a YWU]g' g
fYgcbgVYZf'hY]a a i bcg dd'Yg] Yg]U] g'k \]W WUfUWf]n'ghY
U] UbWX bYcd'U]W]X]g]U] 5h hY ch'Yf' g]XZ' g]YFU' d'U]bg a Un
dfcXi WUb]WbWf' g Vg]UbWg'h Ya cgh]bj Yg]l' U]XcZh'Ya 'fY5'cY
Q%Q'Anff' Q%Q'7UbbU]g'-bX]WQ% Q'UbXA U]bc]UQ% Q'5W]X]b|
lc' hY fYg']g U]U'WY i dlc' bckz' hY a U]b' U]h]WbWf' W]hcl]W
a c'YW'Yg'kci 'XVYfYdfYgbhXVmiUcY'Ya cX]bYZf'Vch' 5'cYJYFU
UbX 5fVcfYg]Wg Q%Q' [i [[i'ghfcbY Zf' Anff' Q%Q' h]fU
\n]fcWbbU]k'X]k'V]QZf' 7UbbU]g% Q'UbX\cbc_]c`Zf'A U]bc]U
Q%Q'Cb'h'Yg'V]g'Ugi XrikUg'dYfZfa YXQ' Anff\

T e Wb]W'fygcbgYkUgYyUi UHXUWfX]b['lc K < C' Vhf]ZVm dgWch YUdY HVLdfcUWzWbglb['cZdfc[fYglj YmfYXgWj Yf]b[fYdU]b['hYfU]c'c[]W'Y La]bU]cbg']bW X]b['7HgWb'UbXD9E h Yd'YUg fYUgUgl]f]h U'Y dYf]YbW'8UUK YfYgUhg]W myj Ui UHX YfYm ' ' a cbhg" DU]Ybg kYfY Ug' UggHX Vm U gdf]h U Vrh.YW]!gei UfYhgUbx.YGh Xbghng'

Clinical Response *								Survival (Years)		
Tumors	n	CR	PR	CR+PR	SD	DC	PD	1	2	3
ALL	132	2	8	10 (8%)	61	71	61	63 (48%)	28 (21%)	16 (13%)
Lung	34	1	0	1	17	18	16	16 (47%)	7 (21%)	6 (18%)
Colon	19	0	2	2	10	12	7	10 (53%)	7 (37%)	4 (21%)
Pancreas	20	0	1	1	8	9	11	9 (45%)	1 (11%)	0
Biliary	11	0	1	1	4	5	6	5 (45%)	3 (27%)	2 (18%)
Stomach	9	1	0	1	3	4	5	2 (22%)	1 (11%)	1 (11%)
HCC	6	0	1	1	3	4	2	3 (50%)	2 (33%)	1 (17%)
Bladder	3	0	0	2	2	2	1	2 (67%)	0	0
Ovarian	14	0	1	1	8	9	5	9 (64%)	3 (21%)	1 (7%)
Melanoma	5	0	2	2	1	3	2	2 (40%)	1 (20%)	1 (20%)
Sarcoma	11	0	0	0	5	5	6	5 (45%)	3 (27%)	1 (9%)

*CR: Complete Response; PR: Partial Response; SD: Stable Disease; DC: Disease Control; PD: Progressive Disease

